22
Participants
Start Date
March 31, 2008
Primary Completion Date
August 31, 2009
Study Completion Date
August 31, 2009
MPC-6827 + Temozolomide
MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Temozolomide at 85 mg/m2 administered orally daily for 21 days in a 4 week cycle.
Cancer Centers of the Carolinas, Greenville
Cancer Centers of Florida, Ocoee
University of Texas MD Anderson Cancer Center, Houston
Huntsman Cancer Institute at the University of Utah, Salt Lake City
The Angeles Clinic, Los Angeles
Lead Sponsor
Myrexis Inc.
INDUSTRY